Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 26.07.2023
Knaus Tabbert AG
First Berlin Equity Research hat ein Research Update zu Knaus Tabbert AG
(ISIN: DE000A2YN504) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 75,00 auf EUR 83,00.
Zusammenfassung:
Wir heben unsere Prognose für 2023 im Vorfeld des für den 10. August
geplanten Q2-Bericht [ … ]
Fri, 21.07.2023
ad pepper media International N.V.
First Berlin Equity Research hat ein Research Update zu ad pepper media
International N.V. (ISIN: NL0000238145) veröffentlicht. Analyst Dr. Karsten
von Blumenthal bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel
von EUR 3,50.
Zusammenfassung:
ad pepper (APM) hat für das zweite Quartal Umsatz und EBITDA ausgewiesen, [ … ]
Fri, 21.07.2023
ad pepper media International N.V.
First Berlin Equity Research hat ein Research Update zu ad pepper media
International N.V. (ISIN: NL0000238145) veröffentlicht. Analyst Dr. Karsten
von Blumenthal bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel
von EUR 3,50.
Zusammenfassung:
ad pepper (APM) hat für das zweite Quartal Umsatz und EBITDA ausgewiesen, [ … ]
Tue, 18.07.2023
Spexis AG
First Berlin Equity Research has published a research update on Spexis AG
(ISIN: CH0106213793). Analyst Christian Orquera reiterated his BUY rating
and maintained his CHF 1.80 price target.
Abstract:
Spexis AG reported FY/22 results which, adjusted for non-cash goodwill
impairment of CHF 3.4m, were roughly as expected. Adjusted EBIT amounted to [ … ]
Tue, 18.07.2023
Spexis AG
First Berlin Equity Research has published a research update on Spexis AG
(ISIN: CH0106213793). Analyst Christian Orquera reiterated his BUY rating
and maintained his CHF 1.80 price target.
Abstract:
Spexis AG reported FY/22 results which, adjusted for non-cash goodwill
impairment of CHF 3.4m, were roughly as expected. Adjusted EBIT amounted to [ … ]
Tue, 18.07.2023
Pharming
First Berlin Equity Research has published a research update on Pharming
Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from EUR 1.80 to EUR 1.50.
Abstract:
Pharming's orphan drug, Joenja, for the treatment of the rare disease,
activated PI3K delta syndrome (APDS), was approved in t [ … ]
Tue, 18.07.2023
Pharming
First Berlin Equity Research has published a research update on Pharming
Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from EUR 1.80 to EUR 1.50.
Abstract:
Pharming's orphan drug, Joenja, for the treatment of the rare disease,
activated PI3K delta syndrome (APDS), was approved in t [ … ]
Wed, 12.07.2023
Diversified Energy PLC
First Berlin Equity Research has published a research update on Diversified
Energy PLC (ISIN: GB00BYX7JT74). Analyst Simon Scholes reiterated his BUY
rating and maintained his GBp 180.00 price target.
DEC looks set to be a prime beneficiary of a multi-year LNG-driven gas
price rally, which is currently in its early stages, but will likely be
su [ … ]
Wed, 12.07.2023
Diversified Energy PLC
First Berlin Equity Research has published a research update on Diversified
Energy PLC (ISIN: GB00BYX7JT74). Analyst Simon Scholes reiterated his BUY
rating and maintained his GBp 180.00 price target.
DEC looks set to be a prime beneficiary of a multi-year LNG-driven gas
price rally, which is currently in its early stages, but will likely be
su [ … ]
Mon, 10.07.2023
MPH Health Care AG
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG
(ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 54,00 auf EUR 59,00.
Zusammenfassung:
Der Net Asset Value (NAV) von MPH belief sich in Q1 auf €188 Mio. gegenüber
€221 M [ … ]
